Korean AI-driven drug discovery speeds up
By Nho, Byung Chul | translator Kang, Shin-Kook
24.05.10 06:00:24
가나다라
0
The Ministry of Science and ICT·MOHW will allocate KRW 34.8 billion in a federate learning-based project to accelerate new drug development
A multi-institution collaborative body for federate learning-based drug discovery is expected to be formed within the first half of the year
'High expandability of platform,' 'Securing ownership of data utilizing technology,' and 'Reducing new drug development cost' expected
▲Ministry of Health and Welfare (MOHW) and the Ministry of Science and ICT will allocate KRW 34.8 billion in AI-driven new drug discovery.
AI-driven new drug discovery through data collaboration among the biopharmaceutical industry, medical institutions, research institutions, universities, and public institutions has accelerated and gained significant attention.
Previously, individual biopharmaceutical companies in South Korea conducted AI-driven new drug discovery through their in-house protocol, and the process was kept confidential.
Starting with the recently organized business group called K-MELLODDY (Machine Learning Orchestration for Drug Discovery), a new system is expected to be implemented within the first half of the year to build upon a system to utilize sources and information related to various clinica
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)